| 11. |
- Kreuzer, M., et al.
(författare)
-
Multidisciplinary European Low Dose Initiative (MELODI) : strategic research agenda for low dose radiation risk research
- 2018
-
Ingår i: Radiation and Environmental Biophysics. - : Springer Science and Business Media LLC. - 0301-634X .- 1432-2099. ; 57:1, s. 5-15
-
Forskningsöversikt (refereegranskat)abstract
- MELODI (Multidisciplinary European Low Dose Initiative) is a European radiation protection research platform with focus on research on health risks after exposure to low-dose ionising radiation. It was founded in 2010 and currently includes 44 members from 18 countries. A major activity of MELODI is the continuous development of a long-term European Strategic Research Agenda (SRA) on low-dose risk for radiation protection. The SRA is intended to identify priorities for national and European radiation protection research programs as a basis for the preparation of competitive calls at the European level. Among those key priorities is the improvement of health risk estimates for exposures close to the dose limits for workers and to reference levels for the population in emergency situations. Another activity of MELODI is to ensure the availability of European key infrastructures for research activities, and the long-term maintenance of competences in radiation research via an integrated European approach for training and education. The MELODI SRA identifies three key research topics in low dose or low dose-rate radiation risk research: (1) dose and dose rate dependence of cancer risk, (2) radiation-induced non-cancer effects and (3) individual radiation sensitivity. The research required to improve the evidence base for each of the three key topics relates to three research lines: (1) research to improve understanding of the mechanisms contributing to radiogenic diseases, (2) epidemiological research to improve health risk evaluation of radiation exposure and (3) research to address the effects and risks associated with internal exposures, differing radiation qualities and inhomogeneous exposures. The full SRA and associated documents can be downloaded from the MELODI website (http://www.melodi-online.eu/sra.html).
|
|
| 12. |
|
|
| 13. |
- BOG, T, et al.
(författare)
-
Oxygen storage material production useful in exhaust gas cleaning catalyst, involves mixing aqueous solution of cerium oxide precursor with aqueous solution of precursor of oxide of metal, and adding first precipitation agent to mixture.
- 2003
-
Patent (populärvet., debatt m.m.)abstract
- NOVELTY - Oxygen storage material production comprises mixing aqueous solution of cerium oxide precursor with aqueous solution of precursor of oxide of metal to form mixture, adding first precipitation agent to mixture to form aqueous suspension containing precipitate, separating precipitate from suspension, drying and calcining precipitate. The oxygen storage material comprises cerium oxide and second oxide of a metal. The metal is alkaline earth metal, rare earth metal, zirconium, zinc, cobalt, copper and/or manganese. USE - The method is useful for producing oxygen storage material useful in exhaust gas cleaning catalyst for purifying exhaust gases of internal combustion engines especially of stoichiometrically operated otto engines. ADVANTAGE - The method provides catalyst that shows excellent activity for purifying harmful pollutant like carbon monoxide, nitrogen oxides, and hydrocarbons. The oxygen storage materials are able to store oxygen in oxidizing atmosphere or release oxygen under reducing conditions, respectively. The oxygen storage material has high specific surface area after thermal aging and improved oxygen storage and release capacity under dynamic exhaust conditions. The storage material shows unprecedented high oxygen storage capacity and excellent dynamic properties with respect to oxygen storage and release compared to conventional materials. DESCRIPTION OF DRAWING(S) - The figure shows setup of precipitation reactor. Precipitation reactor (1) Hydrolysis reactor (2) Tubular flow reactor (3) Precipitation solution (4) Feed (5) Mixer (7) Ph meter (8)
|
|
| 14. |
|
|
| 15. |
- Cannon, Christopher P., et al.
(författare)
-
Design and Rationale of the RE-DUAL PCI Trial : A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
- 2016
-
Ingår i: Clinical Cardiology. - : Wiley. - 0160-9289 .- 1932-8737. ; 39:10, s. 555-564
-
Tidskriftsartikel (refereegranskat)abstract
- Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent thrombosis and coronary events. Triple antithrombotic therapy, typically comprising warfarin, aspirin, and clopidogrel, is associated with a high risk of bleeding. A modest-sized trial of oral anticoagulation with warfarin and clopidogrel without aspirin showed improvements in both bleeding and thrombotic events compared with triple therapy, but large trials are lacking. The RE-DUAL PCI trial (NCT 02164864) is a phase 3b, a strategy of prospective, randomized, open-label, blinded-endpoint trial. The main objective is to evaluate dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and a P2Y12 inhibtor (either clopidogrel or ticagrelor) compared with triple antithrombotic therapy with warfarin, a P2Y12 inhibtor (either clopidogrel or ticagrelor, and low-dose aspirin (for 1 or 3 months, depending on stent type) in nonvalvular AF patients who have undergone percutaneous coronary intervention with stenting. The primary endpoint is time to first International Society of Thrombosis and Hemostasis major bleeding event or clinically relevant nonmajor bleeding event. Secondary endpoints are the composite of all cause death or thrombotic events (myocardial infarction, or stroke/systemic embolism) and unplanned revascularization; death or thrombotic events; individual outcome events; death, myocardial infarction, or stroke; and unplanned revascularization. A hierarchical procedure for multiple testing will be used. The plan is to randomize similar to 2500 patients at approximately 550 centers worldwide to try to identify new treatment strategies for this patient population.
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
|
|
